Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Targeting HOX/PBX dimers in cancer.

Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS.

Oncotarget. 2017 May 9;8(19):32322-32331. doi: 10.18632/oncotarget.15971. Review.

2.

Impact of homeobox genes in gastrointestinal cancer.

Joo MK, Park JJ, Chun HJ.

World J Gastroenterol. 2016 Oct 7;22(37):8247-8256. Review.

3.

The function of homeobox genes and lncRNAs in cancer.

Wang Y, Dang Y, Liu J, Ouyang X.

Oncol Lett. 2016 Sep;12(3):1635-1641. Epub 2016 Jul 21.

4.

Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer.

Fu SW, Kirolikar SP, Ginsburg E, Tan X, Schwartz A, Simmens SJ, Man YG, Pinzone JJ, Teal C, Awate S, Vonderhaar BK, Berg PE.

Oncotarget. 2016 Aug 16;7(33):53204-53216. doi: 10.18632/oncotarget.10633.

5.

The Widening Sphere of Influence of HOXB7 in Solid Tumors.

Errico MC, Jin K, Sukumar S, Carè A.

Cancer Res. 2016 May 15;76(10):2857-62. doi: 10.1158/0008-5472.CAN-15-3444. Epub 2016 Apr 20. Review.

6.

HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24.

Teo WW, Merino VF, Cho S, Korangath P, Liang X, Wu RC, Neumann NM, Ewald AJ, Sukumar S.

Oncogene. 2016 Oct 20;35(42):5539-5551. doi: 10.1038/onc.2016.95. Epub 2016 May 9.

7.

Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells.

Drabovich AP, Pavlou MP, Schiza C, Diamandis EP.

Mol Cell Proteomics. 2016 Jun;15(6):2093-107. doi: 10.1074/mcp.M115.057257. Epub 2016 Apr 11.

8.

CCAR1 5' UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance.

Li G, Wu X, Qian W, Cai H, Sun X, Zhang W, Tan S, Wu Z, Qian P, Ding K, Lu X, Zhang X, Yan H, Song H, Guang S, Wu Q, Lobie PE, Shan G, Zhu T.

Cell Res. 2016 Jun;26(6):655-73. doi: 10.1038/cr.2016.32. Epub 2016 Mar 22.

9.

HOX genes: Major actors in resistance to selective endocrine response modifiers.

Jin K, Sukumar S.

Biochim Biophys Acta. 2016 Apr;1865(2):105-10. doi: 10.1016/j.bbcan.2016.01.003. Epub 2016 Jan 22. Review.

10.

A pivotal role for HOXB7 protein in endocrine resistant breast cancer.

Jin K, Sukumar S.

Oncoscience. 2015 Nov 15;2(11):917-9. eCollection 2015.

11.

Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.

Inoue K, Fry EA.

Genet Epigenet. 2015 Dec 2;7:19-32. doi: 10.4137/GEG.S35500. eCollection 2015. Review.

12.

HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.

Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S.

Cancer Discov. 2015 Sep;5(9):944-59. doi: 10.1158/2159-8290.CD-15-0090. Epub 2015 Jul 15.

14.

Identification of several potential chromatin binding sites of HOXB7 and its downstream target genes in breast cancer.

Heinonen H, Lepikhova T, Sahu B, Pehkonen H, Pihlajamaa P, Louhimo R, Gao P, Wei GH, Hautaniemi S, Jänne OA, Monni O.

Int J Cancer. 2015 Nov 15;137(10):2374-83. doi: 10.1002/ijc.29616. Epub 2015 Jun 17.

15.

HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells.

Lee JY, Hur H, Yun HJ, Kim Y, Yang S, Kim SI, Kim MH.

Int J Biol Sci. 2015 May 1;11(6):701-11. doi: 10.7150/ijbs.11431. eCollection 2015.

16.

MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.

Lü M, Ding K, Zhang G, Yin M, Yao G, Tian H, Lian J, Liu L, Liang M, Zhu T, Sun F.

Sci Rep. 2015 Mar 4;5:8735. doi: 10.1038/srep08735.

17.

HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.

Liu S, Jin K, Hui Y, Fu J, Jie C, Feng S, Reisman D, Wang Q, Fan D, Sukumar S, Chen H.

Cancer Res. 2015 Feb 15;75(4):709-19. doi: 10.1158/0008-5472.CAN-14-3100. Epub 2014 Dec 26.

18.

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.

Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17606-11. doi: 10.1073/pnas.1408650111. Epub 2014 Nov 24.

19.

An E2F1-HOXB9 transcriptional circuit is associated with breast cancer progression.

Zhussupova A, Hayashida T, Takahashi M, Miyao K, Okazaki H, Jinno H, Kitagawa Y.

PLoS One. 2014 Aug 19;9(8):e105285. doi: 10.1371/journal.pone.0105285. eCollection 2014.

20.

P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.

Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, Han L, Xia R, Wang KM, Yang JS, De W, Shu YQ, Wang ZX.

Cell Death Dis. 2014 May 22;5:e1243. doi: 10.1038/cddis.2014.201.

Supplemental Content

Support Center